VKTX Viking Therapeutics Inc: Accounting Value per Share

Viking Therapeutics (VKTX) - corporate logo

Viking Therapeutics (VKTX) faces serious challenges due to a lack of sales and dependence on trial outcomes, which forces the company to conduct secondary offerings. Human capital is maintained through generous stock options and ambitious development projects. The market dynamics of the securities on GURU.Markets stand at 3.51, visualizing the asset's movement. The business relies on the creation of innovative treatments for obesity and liver pathologies.

Viking Therapeutics Inc (VKTX) Equity per Share: for the period 07/04/2022 - 10/29/2026

vikingtherapeutics.com - analytical breakdowns and key metrics (VKTX)

- price and consensus price forecast:
Stock Quotes Viking Pharma|VKTX - Analyst Forecast Prices
- market capitalization data:
Market Valuation Viking Therapeutics, Inc.|VKTX - Business Value
- book capitalization data:
Net Assets per Single Share Viking Therapeutics|VKTX - Accounting Capitalization|Market Capitalization to Book Value Ratio vikingtherapeutics.com|VKTX - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Viking Therapeutics|VKTX - Long-Term Debt to Capital|Short-Term Debt to Equity Viking Therapeutics, Inc.|VKTX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Viking Therapeutics, Inc.|VKTX - Long-Term Debt|Company Current Liabilities Viking Therapeutics
Fundamental company valuation:Viking Pharma, VKTX
Manufactured products of Viking Therapeutics, Inc.

To identify the fundamental leaders of the sector, the analyst evaluates the real value of assets. This indicator reflects the amount of net assets per share after deducting all liabilities. For Viking Therapeutics (VKTX), which relies on investments in the development of GLP-1 drugs, this metric demonstrates capital resilience. The price action of the calculated book value per share reveals the impact of new issuances. Growth in this indicator confirms financial strength prior to product commercialization.

Competitor analysis

Accounting Value per Share Biogen Corp BIIB|Neurocrine Corp (NBIX) - Book Price of a Share|Accounting Value per Share Regencell Bioscience|AXSM (axsome.com) - Equity per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Supernus Pharma - Book Value per Share|Net Asset Value per Share Catalyst Corp CPRX|Accounting Value per Share DNLI (Denali Therapeutics)|harmonybiosciences.com - Book Value per Share|Net Assets per Single Share Biohaven (BHVN)|AMLX: Accounting Value of a Share|Net Assets per Single Share TRVI|Net Asset Value per Share Praxis Corp|Accounting Value per Share Anavex Life Sciences|Net Assets per Single Share ceribell.com|PRTA (Prothena Biosciences) - Book Value per Share|Net Assets per Share ALEC (alector.com)|Net Assets per Single Share ANNX (Annexon Inc.)|Book Value per Share Omeros Corp OMER|Book Value per Share NGNE (Neurogene Inc.)|ACIU: Net Assets per Share|Net Assets per Single Share Voyager Therapeutics, Inc.|Neumora (NMRA) - Equity per Share|Scilex Holding Co. - Book Value per Share|Book Value of One Share Tevogen Bio Inc. (TVGN)|Alpha Cognition (ACOG) - Accounting Value per Share|Accounting Value of a Share Cognition Therapeutics Inc. CGTX|Accounting Value per Share Inhibikase Therapeutics, Inc. (IKT)|Book Price of a Share Cassava Sciences Inc SAVA|Book Value per Share Assertio Therapeutics (ASRT)|COYA - Accounting Value of a Share|Book Value per Share VTGN|OVID (Ovid Therapeutics) - Net Asset Value per Share|ABOS - Net Assets per Single Share|Accounting Value of a Share CervoMed, Inc.|Book Value per Share ATHE|Book Value per Share CLNN (clene.com)|PepGen (PEPG) - Net Assets per Single Share|Share Book Value Jupiter Neurosciences, Inc. JUNS|RLMD (Relmada Therapeutics, Inc.) - Book Value per Share|Annovis Bio Inc (ANVS) - Net Asset Value per Share|GRCE: Accounting Value per Share|Book Value per Share Firefly Neuro|ANEW Medical (KLTO) - Accounting Value per Share|Book Price of a Share NeuroSense Therapeutics, Ltd.|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - Book Value per Share|Net Assets per Share metaviatx.com (MTVA)|NeurAxis, Inc - Book Value per Share|Helius Medical Technologies, Inc. - Accounting Value per Share|Net Assets per Single Share PASG (Passage Bio Corp)|Neuphoria Therapeutics Inc. (NEUP) - Net Assets per Share|Minerva Neurosciences, Inc. (NERV) - Accounting Value per Share|ATHA (Athira Pharma Inc) - Net Assets per Single Share|ADXN (Addex Therapeutics, Ltd.) - Net Assets per Single Share|Book Value per Share Alzamend (ALZN)|Accounting Value per Share Cyclerion Therapeutics|Book Price of a Share protagenic.com PTIX|KTTA - Accounting Value per Share|Cortigent Inc - Equity per Share|Avenue Therapeutics, Inc (ATXI) - Net Assets per Single Share|BCLI - Equity per Share|Book Value per Share CARA|Net Asset Value per Share chromocell.com|ELYM (Eliem Therapeutics, Inc.) - Accounting Value per Share|Book Value per Share ITCI|Longboard Pharma (LBPH) - Net Assets per Single Share|Accounting Value of a Share MRNS (Marinus Pharma)|NKGN: Net Assets per Single Share|NRBO - Net Asset Value per Share|SAGE - Accounting Value per Share|SNPX - Net Assets per Single Share|Trevena, Inc - Book Value per Share|VIGL (Vigil Neuroscience, Inc.) - Net Assets per Share|WENA (Anew Medical) - Net Assets per Single Share|Book Value per Share cerevel.com